Newsroom
View news releases and announcements distributed by EZ Newswire, the trusted source for business news.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
April 4, 2025 6:22 AM
EDT
•
NEW YORK, NY
Sightly Strengthens AI Capabilities with BrandGuard Acquisition
Sightly, a leading data and technology company specializing in real-time marketing solutions, has acquired the assets of Nova AI, Inc., including its BrandGuard® AI-powered brand governance technology. The strategic acquisition strengthens Sightly’s AI capabilities, expands its talent pool, and paves the way for the next phase of its Brand Mentality® platform by helping to enable real-time creative and messaging consistency across content and culture in the age of generative and agentic AI.
Sightly looks to integrate these assets and knowledge set with Brand Mentality’s real-time cultural and contextual intelligence, empowering brands to make real-time media and marketing decisions, deliver ever more authentic messaging and protect their brand identities in today’s dynamic and unpredictable landscape.
The acquisition brings several key benefits to Sightly and its clients:
- Top Talent Additions: Sightly has hired key members from BrandGuard’s Data Science and Engineering teams, enhancing its expertise and bolstering the company’s AI and technological prowess.
- Strategic Advisory: Rob May, CEO and founder of BrandGuard’s parent, Nova AI, Inc., has joined Sightly as special advisor for corporate development and AI strategy. In his new role, Rob will leverage his extensive experience in AI to help shape Sightly’s strategy and vision moving forward. Additionally, Deirdre McGlashan, who previously served as chief marketing officer at BrandGuard, has also taken on an advisory role at Sightly, where she will continue to provide strategic insights to the company.
- Enhanced AI and Brand inputs: BrandGuard’s advanced AI technology complements Sightly’s patented Brand Mentality technology, allowing opportunistic brands and media agencies to respond to breaking news and emerging cultural trends with speed and authenticity.
Adam Katz, CEO of Sightly, commented: “BrandGuard is a natural fit for Sightly. Its innovative AI-powered technology aligns perfectly with our mission to empower brands with real-time insights and the ability to maintain creative and brand suitability controls. This acquisition not only strengthens our AI capabilities but also brings a wealth of expertise that will help us further evolve our Brand Mentality platform. We are thrilled to welcome Rob, Deirdre, and the BrandGuard team to Sightly as we continue to lead the way in driving powerful results for our clients.”
Rob May, CEO and founder of BrandGuard, added: "Joining forces with Sightly creates an incredible opportunity to advance how brands can confidently and effectively engage in real-time marketing. I'm excited to bring BrandGuard's technology and expertise to Sightly's innovative platform and help shape the future of AI-powered marketing solutions."
The acquisition marks an important milestone in Sightly’s growth as its first-ever acquisition, allowing the company to expand its offerings in AI and content strategy, while creating future opportunities to expand into brand governance and providing customers with even more powerful tools for real-time decisions and marketing effectiveness. Sightly celebrates this milestone and remains actively engaged with other strategic opportunities to further drive growth and innovation.
About Sightly
Sightly is a data and technology company dedicated to helping clients achieve their real-time marketing goals. We empower brands and media agencies to connect with culture and maintain brand suitability controls thanks to our Brand Mentality technology, which transforms a brand's unique DNA into a real-time algorithm, enabling marketers to react to trending moments and cultural content with speed and authenticity. Through strategic data partnerships and cutting-edge AI, Sightly provides custom insights that are contextually actionable across YouTube, TikTok, Connected TV, programmatic platforms, and creative development, and is driving powerful results for our clients. For more information, visit https://www.sightly.com.
Media Contact
Alena DeSalvo
marketing@sightly.com
April 3, 2025 6:29 PM
EDT
•
LOS ANGELES, CA
Biohackers World Conference & Expo in LA 2025: Recap and Highlights
The Biohackers World Conference & Expo took place in Los Angeles this past weekend, bringing together nearly 1,000 biohacking enthusiasts, influencers, wellness experts, and technology pioneers at the 1 West Hollywood hotel. The two-day event featured more than 35 speakers, 20 keynote sessions, four panel discussions, and an expo hall showcasing more than 40 exhibitors. This was the first time the event was held in Los Angeles, marking a key gathering for those interested in human optimization and wellness innovation.
Emcee Elias Arjan kicked off the conference with an engaging opening speech, inviting attendees to explore the latest advancements in biohacking, health technology, and performance enhancement.
Day One: Bridging Genetics, Wellness, and Technology in Biohacking
The conference officially opened with a warm welcome from founders Mick Safron and Olia Chernova. They set the stage by sharing their vision for the event: a space where biohacking, wellness, and human optimization come together to empower individuals in taking control of their health and performance.
“Biohackers World is a hub, a movement, and a bridge into a new paradigm in wellness and biohacking—to awaken the light within each person, reminding them of their innate power to heal, optimize, and evolve. Biohacking isn’t a niche anymore; it’s a lifestyle!” said Olia Chernova, co-founder and COO at Biohackers World.
The day featured insightful discussions and cutting-edge research.
- Philipp Samor von Holtzendorff-Fehling, founder of Leela Quantum Tech, explored how quantum energy solutions interact with the body's energy field, demonstrating their potential to enhance daily life.
- Clayton Thomas, founder of The ROOT Brands, provided a roadmap for crafting a personalized biohacking plan, focusing on detoxification strategies and habit alignment.
- Dr. Christina Rahm presented "The Science of Self-Healing," delving into her patented formulations and their impact on cellular health.
- Kashif Khan discussed "Live to 120: Your Genetic Blueprint to Detoxing," emphasizing how personalized detox strategies contribute to longevity.
- Cru von Holtzendorff-Fehling led a healing energy session designed to help women balance their masculine energy, fostering harmony, empowerment, and inner peace.
Women’s Panel: Unlocking True Radiance
A standout moment of the day was the women's panel, moderated by Lea Llovio, featuring Jenny Jones, Dr. Lauren Leiva, Natalia Naila, Jane Emma, and Jennifer Miele. Their discussion, "Radiance Unlocked: The Secret Science of Glowing from Within," explored inner vibrancy, cellular health, and holistic well-being.
Diving Into Cutting-Edge Biohacking Research
- Dr. Sogol Ash and Dr. Russell J. Kort shared their researches on reversing aging and EMF resilience.
- Rachel Lambert and Angie Noack of Braincode Centers led an interactive session on "Neurology of the 1%," integrating brain health insights with leadership strategies.
- Valérie Orsoni, a biohacking pioneer, shared her journey in "Biohacking the Impossible," detailing how peptides, hyperbaric therapy, and bio-identical hormones played a role in reversing chronic conditions.
- Kim Ressler, CEO of SNiP Nutrigenomics, introduced a DNA-tailored nutritional supplement, highlighting the role of precision nutrition in optimizing health.
- Nadège’s insightful session, Unlocking the Pleasure Code, explored wellness and the mind-body connection.
"Longevity Hackers" Documentary Premiere
A highlight of the day was the premiere of "Longevity Hackers," a documentary exploring the future of aging and human potential. Executive producer James Pratt provided exclusive insights and engaged with attendees in a live Q&A session.
Day Two: Advanced Health Strategies and Biohacking Tools
The second day began with a breathwork session led by Dr. Lauren Leiva, designed to clear stagnation, recharge energy, and enhance vitality.
Keynote highlights included:
- Zane Griggs, fitness and longevity coach, who shared strategies for staying fit and high-performing beyond 40.
- A panel featuring Philipp Samor von Holtzendorff-Fehling, Clayton Thomas, and Elias Arjan, discussing the latest in quantum energy, neuroscience, and epigenetics.
- Dr. Jin-Xiong She, Paul Denslow, David Korsunsky, and Dr. Brandon Nwannunu, who explored biomarker testing, microbiome mapping, and strategies for longevity measurement.
- Davinia Taylor explored strategies for managing mental and physical health in a changing world, while Siim Land outlined key components of longevity intelligence with practical steps for long-term well-being.
Attendees also experienced:
- A 30-minute immersive sound bath session with Alisa Galper, blending vibrational frequencies and rhythmic tones to relax the mind and rejuvenate the body.
- A presentation by Richard Sprague on Opticare AI, an innovative system using fundus photography and AI for rapid health insights.
- The final keynote, "Rethinking Your Medicine Cabinet," with Dr. Lisa Piper and Wendy Cohn-Osborne of CODE Health, exploring modern alternatives to common over-the-counter medications.
Throughout the event, attendees participated in giveaways worth more than $15,000, including quantum energy devices, wearable tech, functional supplements, and at-home test kits.
“Bringing Biohackers World to Los Angeles was an incredible experience. LA is a global hub for health, longevity, and innovation, making it the perfect place to unite the biohacking community. The energy was amazing, and with a sold-out event, it's clear that people are eager to take control of their health in new ways,” stated Mick Safron, founder and CEO at Biohackers World.
The Biohacking Expo Hall
The expo hall featured more than 40 exhibitors presenting cutting-edge wellness and biohacking solutions, including wearable tech, personalized health innovations, and holistic wellness tools.
Join Us at the Next Biohackers World Conference & Expo in Chicago
As the event concluded, excitement grew for the next Biohackers World Conference & Expo, set for July 26–27, 2025, in Chicago. The upcoming event promises more pioneering insights, technology showcases, and transformative biohacking strategies.
For more information and to secure your spot, visit Biohackers World.
About Biohackers World
The Biohackers World Conference & Expo is an annual series dedicated to advancing biohacking and human optimization. The conference attracts between 500 and 1,000 attendees and continues to expand globally. For more information, visit www.biohackers.world.
Media Contact
Mick Safron
info@biohackers.world
April 3, 2025 12:11 PM
EDT
•
SHANGHAI, China
CIIE Global Promotion Gains Momentum Across Southeast Asia, Europe and Latin America
In March 2024, three delegations from the China International Import Expo (CIIE) launched a series of global promotional events to boost participation in the 8th CIIE. Spanning across nine countries—Laos, Thailand, Vietnam, Sweden, Italy, Malta, Brazil, Peru, and Ecuador—these initiatives engaged local embassies, industry leaders, and key enterprises, reinforcing the CIIE’s role as a premier platform for global trade and economic cooperation.
In Europe, the delegation underscored the CIIE’s role in fostering cross-border partnerships. Italian businesses, for instance, have been active participants since the CIIE’s inception in 2018, with luxury brands and advanced manufacturing firms leveraging the platform to penetrate China’s consumer market. Swedish companies such as Arjo and Hexagon showcased cutting-edge technology and innovative products in the fields of manufacturing and healthcare at the 7th CIIE, securing promising business opportunities. Meanwhile, Malta has utilized the CIIE to promote its Mediterranean specialty products, attracting strong interest from the Chinese market.
Promotional events in Brazil, Peru and Ecuador highlighted their success stories from previous editions. As a guest country of honor at the 7th CIIE, Brazil spotlighted its growing trade ties with China, notably featuring Luckin Coffee in its national pavilion. Bolstered by upgraded free trade agreements and the CIIE’s support, Peruvian and Ecuadorian exhibitors have seen rising demand for products like squid, avocados, and grapes in China’s vast market.
In Southeast Asia, the promotional group communicated with local representatives about the expanding opportunities provided by the CIIE. Laos views the CIIE as a gateway to global and Chinese market, enhancing economic and trade relations with China. Vietnam has leveraged the CIIE to introduce high-quality local products, securing numerous commercial agreements. Similarly, Thailand has used the platform to promote its specialty goods, further deepening its trade ties with China.
As the 8th CIIE gradually approaches, over 240,000 square meters of the Business Exhibition space have already been booked. With its ever-expanding influence and growing roster of participants, the CIIE continues to set the stage for international trade and investment. Businesses worldwide are invited to join the 8th CIIE this November in Shanghai, China. Explore new opportunities at the official CIIE website: https://www.ciie.org/zbh/en/
About China International Import Expo (CIIE)
The China International Import Expo (CIIE) is a trade fair held in autumn annually since 2018 in Shanghai, China. It is the world's first import-themed national-level expo, featuring exhibitions of multiple countries and businesses and the Hongqiao International Economic and Trade Forum. The expo is co-hosted by the Ministry of Commerce of China and the Shanghai Municipal Government. Its partners include World Trade Organization, United Nations Conference on Trade and Development and United Nations Industrial Development Organization. For more information, visit https://www.ciie.org/zbh/en/.
Media Contact
Cui Yan
exhibition@ciie.org
April 3, 2025 8:45 AM
EDT
•
PHOENIX, AZ
The Rise of Social Seltzers and Functional Drinks: What’s Next for the Non-Alcoholic Boom?
With the rise of functional beverages, social seltzers, and non-alcoholic rituals like Dry January and Sober October, a growing wave of consumers are rethinking how—and why—they unwind. Riding this cultural shift is VIVAZEN, a social drink made from plant-based ingredients that help people relax, Feel Great™, and stay in control—no booze required.
According to a recent NCSolutions survey, 41% of Americans are actively trying to drink less alcohol, and 75% have tried or are interested in trying non-alcoholic alternatives. The study also reveals that consumers are looking beyond just abstaining—they’re actively seeking functional benefits like stress relief, energy, and mood support. That’s exactly where VIVAZEN fits in.
“We’re seeing more and more consumers trading alcohol not just for what they want to avoid—but for how they want to feel,” said Natalie Gershon, chief marketing officer at VIVAZEN. “Our community tells us they love that VIVAZEN helps them relax, connect, and unwind—without sacrificing clarity, sleep, or productivity the next day.”
Made with a proprietary blend of functional botanicals, VIVAZEN is designed to:
- Support relaxation and mood
- Provide a clean, functional Feel Great™ effect
- Fit seamlessly into any social setting—from bars to backyard hangs
Customers echo this sentiment in product reviews and social content, calling VIVAZEN their “go-to drink for winding down after work” and “a must-have for social settings without the pressure to drink.”
As alcohol alternatives continue to evolve beyond sugary mocktails and sparkling waters, VIVAZEN stands out with a purpose-built, plant-powered formula that’s resonating with sober-curious consumers, wellness-minded Millennials, and Gen Z trendsetters seeking more mindful ways to unwind.
VIVAZEN is available in ready-to-drink Alcohol Alternative™ seltzers, botanical gummies, and concentrated wellness shots, available at www.feelgreatbotanics.com and select retail locations nationwide.
Disclaimer: VIVAZEN products are not intended to diagnose, treat, cure or prevent any disease and these statements have not been evaluated by the FDA.
Disclaimer: VIVAZEN products are not intended to diagnose, treat, cure or prevent any disease and these statements have not been evaluated by the FDA.
About VIVAZEN
VIVAZEN fuels Everyday Heroes™ with the power of plants. For over a decade, we've delivered trusted, high-quality botanical supplements that help people power through, focus up, chill out, and boost their mood—without compromise. Rooted in centuries of herbal wisdom and backed by modern innovation, VIVAZEN is a functional, feel-good alternative for those who want to live—and feel—on their own terms. Join the millions who trust VIVAZEN to Feel Great™, naturally and visit https://feelgreatbotanics.com.
About VIVAZEN
VIVAZEN fuels Everyday Heroes™ with the power of plants. For over a decade, we've delivered trusted, high-quality botanical supplements that help people power through, focus up, chill out, and boost their mood—without compromise. Rooted in centuries of herbal wisdom and backed by modern innovation, VIVAZEN is a functional, feel-good alternative for those who want to live—and feel—on their own terms. Join the millions who trust VIVAZEN to Feel Great™, naturally and visit https://feelgreatbotanics.com.
Media Contact
Natalie Gershon
press@vivazen.com
April 2, 2025 11:07 PM
EDT
•
KANSAS CITY, MO
The Power of Community: Aging Forward is on a Mission to Uplift Older Adults Across America
Aging Forward, a national alliance of affiliate organizations, is transforming how society views and supports aging. Since 1972, it has continued championing a future where older adults are not just cared for but celebrated—where longevity is seen as an opportunity rather than a challenge.
With affiliates all over the US and new programs popping up every day, Aging Forward is leading the charge in building stronger, interconnected communities that empower older adults to live with purpose, connection, and dignity. A new affiliate program set to launch in April will bring volunteer transportation services to an underserved area, marking another milestone in the alliance’s mission.
For those involved in these initiatives, the impact is deeply personal. As one leader of a new community effort put it: “I’ve had a successful career, but this—this is by far the hardest thing I’ve ever done. And it’s also the most rewarding.” This sentiment underscores the profound impact that well-designed community programs can have—not only on the older adults they serve but also on those who help build and sustain them.
As the global population shifts, the importance of community-driven initiatives has never been more urgent. Census Bureau research shows that by 2034, older people will outnumber children. This is a first in recorded history. Meanwhile, the World Health Organization estimates that by 2050, the number of people over 60 will have doubled.
Despite these staggering statistics, Sarah Cheney, Executive Director of Aging Forward, emphasizes a different perspective. “The aging population is a beautiful thing. People are living longer lives. So let’s make sure those longer lives are as special as possible.”
Too often, discussions around aging are framed in terms of burdens—on healthcare, on finances, on housing. Aging Forward has been changing this narrative for over 50 years. The goal is not just to extend life expectancy but to enhance quality of life, ensuring older adults remain vibrant, engaged, and valued members of their communities.
Aging Forward was among the first organizations in the country to implement its model of community-driven aging services. Over time, similar initiatives emerged independently, each tailored to the needs of its local population. Now, the alliance is calling for greater collaboration, recognizing that no single organization has all the answers—but together, they can create lasting change. “We can learn from one another,” Cheney affirms. “No one knows your community better than you. And we’ve been working alongside these communities for more than 50 years. Let’s help one another help society.”
One recent example comes from a woman in Florida who was considering a move to Richmond, Virginia, to be closer to her son. The decision wasn’t easy—she was deeply involved in her local community and hesitant to leave behind the connections she had built. But after discovering that Richmond also had a Shepherd Center—one of Aging Forward’s affiliates—she felt confident in making the move. The presence of a supportive, like-minded community was the key factor in her decision.
Stories like these illustrate Aging Forward’s broader vision: a world where every older adult, no matter where they live, has access to the support, education, and social engagement they need to thrive.
The need for robust, well-integrated aging services is only growing. With medical advancements and healthier lifestyles extending life expectancy, the question is no longer just ‘how’ long people will live but ‘how well’ they will contribute to society.
Aging Forward’s model is adaptable, allowing communities to implement programs that align with their unique needs. Whether an organization is just starting, already established, or unaware of the resources available, Cheney encourages collaboration: “We want to make it easier for programs to start, but we also know there are many existing initiatives that could benefit from the resources, credibility, and shared knowledge of a national network. Volunteers and community leaders take pride in knowing they’re part of something bigger.”
This collective approach has already proven invaluable. During the COVID-19 pandemic, Aging Forward affiliates quickly pivoted to offer virtual classes and safety protocols, ensuring that older adults remained engaged and safe despite social distancing restrictions. More recently, as federal funding for aging services has faced uncertainty, organizations within the alliance have leaned on each other for guidance and support, preventing communities from navigating these challenges alone.
Some describe the demographic shift as an age wave or even a silver tsunami—terms that can evoke fear or crisis. But Cheney pushes back against this mindset. “We don’t see this as a problem to solve. We see it as a new chapter in human history. Longevity is an achievement, and we need to approach it with the same optimism we have for childhood development or career growth. Aging should be about living, not just existing.”
Aging Forward envisions a future where no older adult feels isolated, where community support is a given, and where longevity is embraced with enthusiasm. Through strategic partnerships, education, and grassroots efforts, the alliance is making that vision a reality—one community at a time.
And with a goal to expand its affiliate network nationwide, Aging Forward is inviting organizations, leaders, and volunteers to join the movement. “We’ve already reached 165,000 friends,” Cheney says. “But this is just the beginning.”
About Aging Forward
Aging Forward is a national alliance of 55 affiliate organizations, serving over 165,000 older adults annually. We create opportunities for older adults to learn, grow, connect, and give back. United by a shared mission, we support aging as an empowering experience that enriches lives and communities. With the help of dedicated volunteers and partners, we’ve impacted more than 2.5 million older adults—and we’re just getting started! For more information, visit https://aging-forward.org.
About Aging Forward
Aging Forward is a national alliance of 55 affiliate organizations, serving over 165,000 older adults annually. We create opportunities for older adults to learn, grow, connect, and give back. United by a shared mission, we support aging as an empowering experience that enriches lives and communities. With the help of dedicated volunteers and partners, we’ve impacted more than 2.5 million older adults—and we’re just getting started! For more information, visit https://aging-forward.org.
About Aging Forward
Aging Forward is a national alliance of 55 affiliate organizations, serving over 165,000 older adults annually. We create opportunities for older adults to learn, grow, connect, and give back. United by a shared mission, we support aging as an empowering experience that enriches lives and communities. With the help of dedicated volunteers and partners, we’ve impacted more than 2.5 million older adults—and we’re just getting started! For more information, visit https://aging-forward.org.
Media Contact
Sarah Cheney
sarah@aging-forward.org
April 2, 2025 10:49 PM
EDT
•
İSTANBUL, Türkiye
MedArt Hair Clinic Opens New Office in the UK after Hiring GMC-Certified Surgeon
MedArt Hair Clinic, a leader in Turkey's internationally acclaimed hair transplant industry, has officially opened its first office in the United Kingdom. This strategic expansion makes the clinic's renowned expertise in advanced hair restoration techniques more accessible to UK patients while maintaining the cost advantages that have made Turkish hair transplants so sought-after globally.
"Opening our UK office represents a significant milestone in our mission to provide world-class hair restoration solutions," says Fikret Doğrucu, CEO of MedArt Hair Clinic. "Our UK patients can now receive the same exceptional care and results we're known for in Istanbul, with the added convenience of pre-operative consultations and post-operative support right here in the UK."
Bridging Turkish Excellence with Local Convenience
MedArt Hair Clinic has built its reputation on combining surgical precision with artistic hairline design, performing thousands of successful hair transplant procedures for patients from across Europe, North America, and the Middle East.
The new UK office addresses a critical gap in the medical tourism experience by providing face-to-face consultations with UK-based specialists trained in MedArt's protocols. Patients benefit from comprehensive pre-operative assessments using advanced diagnostic technology and detailed treatment planning before traveling to Turkey.
After their procedure, they can access local aftercare support and maintain direct communication with the surgical team in Istanbul throughout their recovery journey.
This dual-location approach creates a seamless experience that combines the affordability of Turkish medical procedures with the convenience and reassurance of local support.
Why Turkish Hair Transplants Continue to Lead the Market
Turkey has established itself as the global center for hair restoration, with good reason. MedArt Hair Clinic exemplifies why Turkish clinics dominate this specialized field.
The clinic offers a complete spectrum of cutting-edge procedures, including Sapphire FUE, DHI, Long Hair FUE, and Stem Cell Hair Transplant therapies. MedArt's surgeons perform only 2–3 hair transplant surgeries at most on a given day, maintaining world-class medical standards with detailed attention. From meticulous hairline design to high-density graft placement, every aspect of the procedure is optimized to ensure natural-looking, long-lasting results.
Perhaps most importantly for patients, MedArt's procedures cost 60–70% less than equivalent treatments in the UK without compromising quality. The clinic provides all-inclusive packages where luxury accommodation, private transfers, and comprehensive aftercare are standard, eliminating the stress of coordinating these elements separately.
The typical hair transplant cost in Turkey at MedArt is £2,000 to £4,000, including accommodation and transfers, while the cost for a state-of-the-art hair transplant in the UK ranges from £8,000 to £15,000.
Specialized Techniques Set MedArt Apart
Specialized Techniques Set MedArt Apart
MedArt Hair Clinic has distinguished itself through mastery of multiple hair restoration techniques. The clinic's surgeons are experts in Sapphire FUE, using sapphire-tipped instruments for precise, minimally invasive follicle extraction and placement that promotes faster healing and reduces scarring.
They also excel in DHI (Direct Hair Implantation), utilizing specialized Choi implanter pens for simultaneous site creation and implantation, delivering outstanding graft survival rates, and allowing for no-shave options.
For patients who prefer to maintain their appearance during the procedure, MedArt offers Long Hair FUE, allowing them to keep longer hair during the transplant for immediate visualization of results.
Additionally, their Stem Cell Hair Treatment provides regenerative therapy that enhances native hair growth and strengthens transplanted follicles for improved long-term outcomes.
Unlike many competitors, MedArt's surgical team has extensive experience with diverse hair types, including Afro-Caribbean, Asian, and Middle Eastern hair textures, making their services accessible to the UK's multicultural population.
The MedArt Difference
MedArt's approach to hair restoration goes beyond technical excellence. The clinic has pioneered a patient-centered methodology emphasizing personalized care at every step for the best hair transplant in Turkey, separating themselves from “hair-mill” like competitors. Their surgeons create age-appropriate, natural-looking hairlines customized to each patient's facial structure rather than following generic templates. The clinic recommends only the necessary number of grafts for optimal results rather than maximizing procedure size, prioritizing ethical treatment planning over profit.
The surgical team considers future hair loss patterns when designing treatment plans, ensuring results will continue to look natural as patients age. Throughout the process, MedArt provides transparent communication about results and recovery, setting realistic expectations from the start. Beyond the procedure itself, the clinic offers lifetime support and ongoing guidance for maintaining transplant results.
Transforming the UK Hair Transplant Experience
The UK office opening represents a paradigm shift in how British patients can approach hair restoration. For UK patients, this means elimination of communication barriers through local representatives who understand both Turkish surgical protocols and British healthcare expectations. Patients experience reduced travel anxiety with comprehensive pre-trip preparation and confidence in receiving consistent care standards both in the UK and Turkey. They gain access to immediate in-person support for any post-operative concerns and benefit from simplified coordination of medical records and treatment plans between both facilities.
The UK facility includes state-of-the-art diagnostic equipment for detailed hair and scalp analysis, allowing the team to create comprehensive treatment plans before patients travel to Istanbul.
Looking Ahead: Expanding Medical Tourism Support
With the successful launch of the UK office, MedArt Hair Clinic is already exploring additional European locations to better serve its international patient base.
"This expansion is just the beginning," confirms Doğrucu. "We're committed to making world-class hair restoration accessible to more people, combining Turkish surgical excellence with local convenience in key markets."
The clinic anticipates treating over 2,000 UK-based patients in the first year of operations, with continued growth expected as awareness of this hybrid care model increases.
For more information about MedArt Hair Clinic's services or to book a consultation at the new UK office, visit www.medarthair.com/en.
About MedArt Hair Clinic
Founded in 2015, MedArt Hair Clinic has established itself as a premier destination for hair restoration, combining surgical expertise with artistic design principles. With its main surgical center in Istanbul and the new UK consultation office, MedArt continues to set standards for excellence in the field of hair transplantation. For more information, visit www.medarthair.com.
About MedArt Hair Clinic
Founded in 2015, MedArt Hair Clinic has established itself as a premier destination for hair restoration, combining surgical expertise with artistic design principles. With its main surgical center in Istanbul and the new UK consultation office, MedArt continues to set standards for excellence in the field of hair transplantation. For more information, visit www.medarthair.com.
Media Contact
Fikret Doğrucu
info@medarthair.com
April 2, 2025 6:25 PM
EDT
•
LAS VEGAS, NV
A Higher Calling: Area 52's Snow Caps Cannabis Flower
In a market flooded with pretenders, Area 52 stands alone with its Snow Caps cannabis flower—a crystalline manifestation of five years dedicated to botanical perfection. Lauded across platforms and crowned by discerning publications, this isn't merely another product launch; it's the continuation of a legacy that refuses compromise.
The distinction is immediately apparent. While knockoffs adopt our visual language—attempting to mirror packaging that took years to perfect—they cannot replicate what matters: the experience. The first inhale tells the truth that marketing cannot obscure. Our Snow Caps deliver what others only promise in premium THCA flower.
This isn't arrogance—it's acknowledgment of craftsmanship. Each batch undergoes scrutiny that would eliminate most competitors before reaching consumers. Our standards remain immovable while others cut corners, hoping you won't notice the difference. We know you will.
For the initiated seeking authenticity in cannabis—whether exploring our Delta 9 THC UFO Gummies, our precision-engineered Disposables, or our therapeutic Focus and Pain formulations—Area 52 offers sanctuary from mediocrity. Our original Snow Caps THCA flower stands as testament to our refusal to follow when we were born to lead—coming in a pre-roll and whole-flower format.
The invitation remains open. Join those who understand that excellence isn't an accident but a deliberate choice made thousands of times. From our Liquid Diamonds technology to our carefully calibrated THC gummies, we create with intention that resonates in every product.
Discover why, for half a decade, those who know have turned to Area 52. Not because we claim greatness, but because we deliver it—consistently, unapologetically, and with a clarity that speaks for itself.
This is cannabis elevated beyond commerce. This is Area 52.
About Area 52
Based in Las Vegas, Area 52 is a leader in the cannabis industry, dedicated to innovation and quality. We offer premium, third-party-tested products designed for purity and potency, delivering an elevated experience to our customers. Learn more at https://area52.com.
About Area 52
Based in Las Vegas, Area 52 is a leader in the cannabis industry, dedicated to innovation and quality. We offer premium, third-party-tested products designed for purity and potency, delivering an elevated experience to our customers. Learn more at https://area52.com.
Media Contact
Adam Smith
ufo@area52.com
April 2, 2025 5:46 PM
EDT
•
NASHVILLE, TN
TuneHatch’s $1 Million Giveback to Independent Artists: Giving Control and Cash to its Musicians in 2025, Onward
TuneHatch, the next-gen show management platform dedicated to making live music and entertainment more transparent, efficient, and profitable for artists, promoters, and venues alike, just announced its groundbreaking “Built to Give Back” initiative, designed to boost earnings for the creative community during a time when every dollar counts. For all of 2025 and beyond, any artist or promoter that creates a ticket link on TuneHatch will get a cash bonus of up to $5 per ticket sold, paving the way for bolder, more profitable touring and concerts. Their venue “Built to Give Back” initiative will be announced in Summer 2025.
Putting Artists First
The concept behind “Built to Give Back” is simple: When you list a show on TuneHatch, for every ticket you sell, TuneHatch sends bonus cash back to your account. This extra money can be paid out to anyone on the line up after the show.
“We built TuneHatch because we believe that independent artists deserve a fair shot at making a living doing what they love,” said Christal Hector, founder and CEO at TuneHatch. “Our ‘Built to Give Back’ initiative is an extension of that mission, ensuring our users can quickly and easily ticket their events while making more money to fuel their careers.”
In a landscape where fees can pile up and cut into earnings, especially for small and independent artists and organizers, TuneHatch is stepping in to give them the power to fund their careers and fuel their passion—at no cost!
$1 Million Giveback
TuneHatch boldly seeks to give back $1 million through this initiative. But how? Just 20 tickets sold can net artists $100 extra on a show. With 10,000 artists listing their shows, TuneHatch could give back over $1,000,000 this year alone.
The $1 million giveback is powered by the very people it’s designed to support. When artists and promoters choose to list their shows on TuneHatch, they’re not just increasing their own earnings—they’re fueling a system that gives back to the entire live music community. Like the classic “buy one, give one” movement, every show added helps grow the impact, turning everyday participation into meaningful change.
Why Support “Built to Give Back”?
- Boost community growth: By putting money back into the hands of artists, TuneHatch fosters a community where artists and organizers can focus on building memorable experiences that bring people together.
- Support emerging artists: For up-and-coming performers, budgets are tight and every dollar counts. Being able to make more money on each ticket sale gives new talent the boost they need to refine their art, attract new fans, and advance their careers.
- Sustainable growth: When artists and organizers make more revenue, they can reinvest in marketing, production, and future shows. This cycle of reinvestment leads to thriving events that benefit both artists and fans alike.
How It Works
- Sign up or log In: Create a free TuneHatch account or log in to your existing one.
- Create a listing: Post your upcoming event, whether a concert, comedy show, or any other live performance event.
- Get paid: Watch as you make extra money on every ticket sold, in real time from your artist dashboard on TuneHatch—you can pay yourself and your lineup immediately after the show concludes. No waiting period, no extra fees!
- Tell a friend: Help other artists make more money by sharing your listings and telling them about the “Built to Give Back” initiative.
For a detailed explanation of how it works, visit the TuneHatch “Built to Give Back” resource page.
The Road Ahead
With the launch of “Built to Give Back,” TuneHatch cements its commitment to nurturing a thriving community of artists and organizers who work tirelessly to bring people together through unforgettable shows. This campaign isn’t just about the money—it’s about sparking a movement that challenges ticketing norms, for the benefit of the creative community. When more creators can invest in their passion, fans benefit from more high-quality, diverse events.
“TuneHatch is dedicated to bridging the gap between artists, their fans, and the rest of the music ecosystem,” added Will Pellerin, a Nashville-based TuneHatch artist and former contestant on The Voice. “When artists and organizers keep more of their earnings, they invest back into the creative process. Everyone—from the organizer to the attendee—wins.”
Join the Movement
TuneHatch’s “Built to Give Back” Campaign aims to bolster an already passionate community of live music artists and organizers, helping them focus on what truly matters: creating unforgettable experiences for their fans.
- Sign up: If you’re an artist or event organizer looking to earn more on your shows, sign up on TuneHatch for free, today.
- List an event: It takes less than 5 minutes to launch your event and start getting paid.
- Tell a friend: Share the news and amplify the impact.
Join TuneHatch’s “Built to Give Back” initiative for free today!
About TuneHatch
TuneHatch is a live event platform that makes it easy for artists, promoters, and venues to book, promote, and ticket shows—all in one place. Designed for transparency, speed, and simplicity, TuneHatch helps performers and venues spend less time on admin and logistics and more time doing what they love: putting on great shows. With accessible tools and a community-first approach, our “Built to Give Back” initiative reflects our mission to support independent talent and bring people together through unforgettable live experiences. Learn more at tunehatch.com.
Media Contact
Christal Hector
media@tunehatch.com
April 2, 2025 9:53 AM
EDT
•
NEW YORK, NY
TrialKit Launches AI-Powered Legal Discovery Platform, Secures $4.25M Seed Funding to Transform Criminal Defense
TrialKit, an AI-powered discovery platform built for criminal defense attorneys, today announced its public launch alongside a $4.25 million seed round led by UpWest, with participation from 97212 Ventures, Kaedan Capital, and NYU Law’s Entrepreneurship & Venture Capital Program. The company provides an end-to-end, AI-native legal discovery platform designed specifically to help defense attorneys manage the overwhelming volume of digital evidence in modern criminal cases.
“I’ve been in the shoes of the attorney at 2 a.m. trying to find the one moment in a body cam that could change everything. TrialKit was born out of that experience — to help attorneys cut through the chaos, stay organized and focus on building the strongest defense possible,” said Ariel Deshe, co-founder and CEO of TrialKit.
Over the past decade, the volume of digital evidence in criminal cases has exploded, dramatically outpacing the tools attorneys have available. In Colorado, for example, public defenders have reported discovery volume growing by 4,500%. That growth has added pressure to an already overburdened system, where attorneys need far more time and resources to properly review discovery, prepare cases, and advise clients at every stage.
TrialKit streamlines legal discovery by leveraging AI to analyze massive datasets in minutes, rather than weeks or months. Specific features include:
- Automated Organization & Categorization: Automatically ingests and labels messy, unstructured discovery.
- AI-Powered Search Across All File Types: Converts and translates all files (videos, PDFs, audio, etc.) into searchable text.
- Entity Extraction & Cross-Reference Mapping: Identifies people, locations, and times across thousands of files.
- Facial Recognition for Video Review: Detects and catalogs faces in body-worn camera footage and surveillance video.
- Interactive Workstation for Trial Prep: Integrates tools for note-taking, fact mapping, and witness preparation, allowing attorneys to analyze discovery and get case-ready in one secure workspace.
Already in use by more than 20 leading criminal defense firms and in public criminal defense cases across the U.S., TrialKit has received strong early traction.
“TrialKit fundamentally transforms discovery,” said Jason Kosloski, Partner at Koslowski Law. “As even the most routine cases are quickly ballooning in size, TrialKit is a force-multiplier that saves hours and hours of organizing and makes the process of reviewing and finding connections within discovery infinitely easier.”
“The burden of discovery is one of the biggest challenges in today’s criminal justice system, and TrialKit has created a truly groundbreaking solution,” said Gil Ben-Artzy, founding partner at UpWest. “By bringing AI-powered intelligence to the legal field, they’re helping level the playing field for defense attorneys who have been operating at a disadvantage for far too long.”
TrialKit is now available to criminal defense firms across the country. Legal professionals interested in learning more can request a demo at TrialKit.ai.
About TrialKit
Built by attorneys for attorneys, TrialKit empowers litigators by transforming overwhelming discovery into a dynamic, searchable case file. With AI-driven analysis, fact visualization and seamless collaboration, attorneys can surface key evidence faster, reduce costs and build stronger defenses within a secure, intuitive platform. Founded in 2023 by former public defender Ariel Deshe, TrialKit has raised $4.25 million from UpWest, 97212 Ventures, Kaedan Capital, and NYU Law’s Entrepreneurship & Venture Capital Program. Today, law firms across the U.S. rely on TrialKit to streamline discovery, strengthen their defenses, and meet the growing demands of digital evidence. For more information, visit https://www.trialkit.ai.
Media Contact
Katy Goldstein
katy@katygoldsteincomms.com
April 2, 2025 9:44 AM
EDT
•
ASHBURN, VA
Quoin Reports Clinically Meaningful Whole Body Response to QRX003 in Pediatric Netherton Syndrome; Second Patient Cleared for Dosing
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced additional encouraging clinical findings from its ongoing investigator-led study in pediatric Netherton syndrome (NS). After six weeks of continuous whole body treatment with QRX003, the enrolled pediatric patient continues to demonstrate significant clinical benefit, including visibly healed skin, sustained relief from symptoms, and elimination of the need for previously required medications.
Specifically, the patient’s skin remains almost entirely healed, underscoring the durability of effect seen with ongoing daily use of QRX003. Importantly, the subject has not required prior medications such as antibiotics, antivirals, antihistamines, or glucocorticoids. The patient’s pruritus (itch) remains virtually eliminated, leading to the continuation of restful, uninterrupted sleep—described by the study team as the first sustained period of undisturbed sleep in the patient’s life. No adverse events have been reported after six weeks of full body exposure to QRX003.
Based on these results, Quoin has received approval to initiate testing of a second pediatric patient under the same whole body treatment protocol.
Dr. Michael Myers, CEO of Quoin, commented: “We’re very encouraged to see continued improvement in this first pediatric patient following whole body application of QRX003. Her skin is now almost completely healed, and she remains free from previously required medications. Most notably, the pruritus that has severely impacted her quality of life since birth is now nearly eliminated, and she is finally experiencing uninterrupted sleep without the need for sedatives.
These outcomes provide strong evidence that QRX003 may be addressing the underlying pathology of Netherton syndrome—not just managing symptoms. The absence of adverse events after six weeks of full-body exposure is also highly encouraging. With approval now granted to initiate treatment in a second pediatric subject, we look forward to continuing this important study and reporting further updates.”
About Quoin Pharmaceuticals
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton syndrome, peeling skin syndrome, SAM syndrome, palmoplantar keratoderma, scleroderma, epidermolysis bullosa, microcystic lymphatic malformations, venous malformations, angiofibroma, and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as “expect,” “intend,” “hope,” “plan,” “potential,” “anticipate,” “look forward,” “believe,” “may,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: the potential efficacy of QRX003 as a treatment for Netherton syndrome; testing expected to commence in a few weeks on a second pediatric patient; continue with our plans to further expand this study to include additional pediatric subjects; and Quoin’s products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton syndrome, peeling skin syndrome, SAM syndrome, palmoplantar keratoderma, scleroderma, epidermolysis bullosa, microcystic lymphatic malformations, venous malformations, angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to deliver a safe and effective treatment for Netherton syndrome; whether the Company’s studies successfully generate data that is sufficiently robust and comprehensive to support an NDA filing for QRX003 as an approved treatment for Netherton syndrome; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
Media Contact
Kerry Corbit
Kerry@pcgadvisory.com
April 2, 2025 9:00 AM
EDT
•
LOS ANGELES, CA
Exclusive: everle – A New Social Network Quietly Built to Heal the Digital World
In a time when digital platforms permeate every corner of life, meaningful connection has become increasingly rare. Enter everle, the first subscription-based social networking platform designed entirely around genuine connection, mental well-being, and member empowerment — not ad dollars or viral trends.
“While other platforms optimize for engagement, virality, and surveillance-driven monetization, everle is taking a radically different path,” said Tessa Adams, founder of everle. “We’ve been quietly and deliberately building a better way — one that prioritizes depth over dopamine, belonging over broadcasting, and well-being over likes.”
As growing concerns mount over the direction of mainstream digital platforms, recent events highlight the urgency of a new approach. There continues to be a critical gap in today’s digital ecosystem: platforms built for speed, scale, or secrecy — but not for trust, intentionality, or humanity.
everle is not just another social app. It’s a movement to make digital spaces feel human again.
With no ads, no addictive algorithms, and no data harvesting, everle is flipping the script on social networking by putting members — not corporations — in control of their online experience.
With no ads, no addictive algorithms, and no data harvesting, everle is flipping the script on social networking by putting members — not corporations — in control of their online experience.
The everle team is a group of outside of the confines of Silicon Valley who are tired of the status quo, including NSYNC member Lance Bass, who has been a passionate advocate for mental health and digital wellness. “I believe in everle because it’s exactly what we need right now — a space that’s real, supportive, and rooted in human connection,” said Bass.
The platform is currently rolling out to a growing waitlist of over 100K with invites to those seeking authentic, healthy, and thoughtful online interactions to join the movement.
About everle
everle is the first online social networking platform designed for the everyday human — built around data privacy, mental well-being, and intentional connection. Ad-free, algorithm-free, and powered by a subscription model, everle is redefining what it means to belong in the digital age. Learn more at everle.com.
everle is the first online social networking platform designed for the everyday human — built around data privacy, mental well-being, and intentional connection. Ad-free, algorithm-free, and powered by a subscription model, everle is redefining what it means to belong in the digital age. Learn more at everle.com.
Media Contact
hello everle
hello@everle.com
April 2, 2025 9:00 AM
EDT
•
WASHINGTON, DC
Actor and Producer Charlie Day to Keynote 2025 OAAA OOH Media Conference as Full Agenda Goes Live
The Out of Home Advertising Association of America (OAAA) today unveiled the full agenda for its 2025 OOH Media Conference, taking place May 5–7 in Boston, with a headlining keynote by actor, writer, and producer, Charlie Day. With powerhouse marketers, agency executives, media analysts, and industry thought leaders set to take the stage, this year’s event promises to be a bold exploration of the expanding role of out of home (OOH) in the modern marketing mix.
Charlie Day, best known for co-creating and starring in It’s Always Sunny in Philadelphia, will bring his signature energy and offbeat perspective to the main stage. In addition to his on-screen success, Day has expanded his creative footprint as an entrepreneur with the launch of Four Walls Whiskey. His keynote will explore how bold storytelling, cultural resonance, and creative risk-taking can drive real-world impact. Underscoring this year’s conference theme, “The Power of Presence,” his session will spotlight how showing up in authentic, unexpected ways can leave a lasting mark on culture and consumers alike.
The 2025 agenda features a who’s-who of brand and media leaders, including:
- Kraft Heinz’s North America CMO, Todd Kaplan in a headline session on creativity, culture, and striking the balance between creativity and data, moderated by David Shing
- A chief marketing officer roundtable with trailblazing marketers from Bose, New Balance, and CBRE on growth strategies and cutting through the noise
- Cracker Barrel’s CMO Sarah Moore on balancing tradition with innovation across social, digital, and loyalty marketing
- Generational researcher Jason Dorsey returns to the OOH Media Conference stage unpacking how younger generations think about media, brands, and the workplace
- A powerhouse panel of women leaders from Rakuten, Infillion, Gemini, and Intersection on breaking barriers and building brands
- Media strategist Brian Wieser on current trends impacting the ad economy and the industry's future, examining shifting dynamics and what these changes mean for how money will flow in a rapidly transforming environment
- A candid conversation with the chief executives of the three largest U.S. OOH companies: Clear Channel Outdoor, Lamar Advertising and OUTFRONT Media
- A high-impact media investment discussion with senior executives from major agency holding companies on OOH’s growing role in the media mix
- Brand leaders from HubSpot, Lesser Evil, and Lalo on how innovative brands are adapting to a rapidly changing media and platform ecosystem, shifting consumer behaviors, and economic complexity
- A pharma marketing case study with AstraZeneca on how programmatic DOOH is reshaping patient engagement
- LUMA Partners’ Terence Kawaja on how AI, automation, and retail media are redefining the future of OOH
“The 2025 OOH Media Conference showcases the full power and momentum of the out of home industry,” said Anna Bager, President and CEO, OAAA. “This year’s agenda is our most ambitious yet—featuring an inspiring keynote from Charlie Day, plus dynamic conversations with brand leaders, media innovators, and creative visionaries from every major sector. It reflects how far out of home has come and boldly charts where we’re heading next—thriving at the intersection of creativity, technology, commerce, and culture.”
The 2025 OOH Media Conference will also feature deep-dive track sessions and workshops, the 83rd Annual OBIE Awards, the bi-annual OOH Industry Awards, and countless opportunities for networking, inspiration, and industry celebration over three packed days.
To view the full agenda and register for the 2025 OOH Media Conference, visit ooh2025.com/agenda.
About the Out of Home Advertising Association of America (OAAA)
The Out of Home Advertising Association of America (OAAA) is the national trade association for the entire out of home (OOH) advertising industry. OAAA represents over 850 members, including leading media companies, advertisers, agencies, ad-tech providers, and suppliers. OOH media includes billboards, street furniture, transit, place-based media, and digital formats (DOOH) across every sector of the channel. OAAA is the unifying voice for the industry, the authoritative thought leader, and the passionate advocate for advancing OOH advertising in the United States. The legislative unit of OAAA advocates for the responsible growth of OOH with federal, state, and local governments. OAAA-member media companies donate over $500 million annually in public service advertising. Founded in 1891, OAAA is headquartered in Washington, DC, with offices in New York City. For more information, visit https://oaaa.org.
Media Contact
Cassady Nordeen
cassady@purposenorthamerica.com
April 1, 2025 8:59 AM
EDT
•
MADRID, Spain
Kazakhstan’s EA Ventures and Plug and Play Launch €20 Million Fund to Support European Startups
EA Ventures, the venture capital arm of EA Group Holding, has partnered with global innovation platform Plug and Play to launch a €20 million investment fund aimed at accelerating early-stage startups across Europe. Based in Madrid, Spain, the fund is hosted by Plug and Play EMEA Fund Management Company, a regulated entity managing venture initiatives across Europe, the Middle East, and Africa.
The EA Ventures Plug and Play EMEA Fund will focus on seed-stage investments in high-impact technologies, including artificial intelligence, enterprise solutions, fintech, sustainability, mobility, and e-commerce. With ticket sizes ranging from €200,000 to €500,000, the fund aims to back 30–35 promising European startups.
“Spain is entering a new wave of tech entrepreneurship, and we see an opportunity to bring a fresh perspective rooted in global connectivity and agile capital. This partnership enables us to tap into Europe’s deep talent pool while helping founders think and grow beyond borders,” said Yerik Aubakirov, CEO of EA Group Holding.
Officially launched on March 3, 2025, the fund offers portfolio companies access to financial backing, expert mentorship, and Plug and Play’s extensive international network of corporations, investors, and advisors.
“We believe in the immense potential of the Spanish territory and aim to provide both financial and strategic support. Our goal is to connect the best founders with international hubs, enhancing their global reach and agility,” said Seena Amidi, Managing Partner EMEA at Plug and Play Tech Center.
This collaboration brings together Plug and Play’s global acceleration platform with EA Ventures’ dynamic, founder-first investment approach — with the goal of driving innovation and entrepreneurship across Europe.
About EA Ventures and EA Group Holding
EA Ventures, the venture capital arm of EA Group Holding, invests in high-potential startups in the fintech, health tech, blockchain and SaaS sectors. Since 2021, we have focused on seed and pre-Series A companies, offering investments ranging from $500,000 to $2 million. Led by an experienced team of investment professionals and entrepreneurs, the fund leverages our industry expertise to identify and support promising startups, primarily in Europe, with an emphasis on Spain. As part of EA Group Holding, EA Ventures provides portfolio companies with capital, strategic guidance, operational support and access to an international network to help drive sustainable growth and long-term success. For more information, visit eagroup.com.
About Plug and Play
Plug and Play is the leading innovation platform connecting startups, corporations, venture capital firms, universities, and government agencies. Headquartered in Silicon Valley, we operate in 60+ locations across five continents. We offer corporate innovation programs and support our partners through every stage of their innovation journey — from education to execution. We also run startup acceleration programs and manage over $1 billion in assets under management across our funds. Our portfolio includes hundreds of successful companies such as Dropbox, PayPal, Guardant Health, Honey, N26, Rappi, and Turing. For more information, visit https://www.plugandplaytechcenter.com.
Media Contact
Jeanna Skripal
skripal@itcomms.io
March 31, 2025 12:03 PM
EDT
•
TALLINN, Estonia
Motorsport Meets the Future of Finance: CryptoProcessing by CoinsPaid Joins Forces with Eduardo and Fernando Barrichello
CryptoProcessing by CoinsPaid is pleased to announce Eduardo “Dudu” and Fernando “Fefo” Barrichello as official brand ambassadors for 2025. This strategic partnership at the intersection of motorsport and digital finance underscores the shared values of precision, adaptability, and a forward-thinking approach to innovation.
In a sport where every millisecond counts, the unmatched speed and precision of digital finance are becoming more crucial than ever. With Eduardo competing in the FIA World Endurance Championship (WEC) for Racing Spirit of Léman (#10 Aston Martin Vantage AMR GT3 Evo), and Fernando racing in Euroformula Open for Team Motopark (#41 Dallara 324), this partnership brings together the next generation of elite racing talent with the latest evolution of payments.
Max Krupyshev, CEO of CryptoProcessing by CoinsPaid: “Motorsport is about making split-second decisions at over 200 mph. The same goes for digital finance—there’s no time for slow transactions. Technology progresses in cycles—things that once seemed complex become second nature. At one point, electronic fuel injection was a radical innovation in motorsport. Now, it’s essential. The same applies to digital payments. Eduardo and Fernando represent a new generation that understands how innovation shapes the future, and we’re proud to have them on board.”
Barrichellos: Speed, Legacy & Innovation
The Barrichello name is legendary. Their father, Rubens Barrichello, remains one of the most respected figures in Formula 1 history. But Eduardo and Fernando are carving out their own path in the most competitive racing championships on the planet.
Now, they’re not just redefining motorsport—they’re helping drive the future of digital payments.
Eduardo Barrichello: “Racing is all about precision and adaptability, and that’s exactly what Web3 is bringing to the world of finance. CryptoProcessing by CoinsPaid is making digital transactions more intuitive and accessible, and that’s something I’m excited to be part of.”
Fernando Barrichello: “Whether it’s on track or in fintech, the goal is the same: be faster, be more efficient, and always stay ahead of the curve. Partnering with CryptoProcessing by CoinsPaid is like unlocking DRS on the future of finance, its about highlighting how innovation can simplify complex systems, whether in motorsport or global payments.”
A Shared Commitment to Innovation
This partnership is built on a shared vision of progress and adaptability, demonstrating how technology can drive new standards across sectors. CryptoProcessing by CoinsPaid isn’t just another crypto company—it is one of the leaders in digital payments, offering seamless, secure, and efficient solutions that are transforming industries worldwide.
The Future of Racing & Finance Starts Now
Motorsport is built on innovation, and so is Web3. CryptoProcessing by CoinsPaid and the Barrichello brothers are proving that crypto payments aren’t just the future—they’re here, and they’re faster than ever.
The grid is set. The lights are out. 2025 is going full throttle.
About CryproProcessing
CryptoProcessing by CoinsPaid is a trusted provider of cryptocurrency payment solutions for businesses, connecting them with a growing market of over 650 million crypto users worldwide. With over a decade of cryptocurrency expertise, CryptoProcessing serves hundreds of merchants globally across industries, offering seamless integration and support for a wide range of cryptocurrencies to make accepting crypto payments simple and cost-efficient. To learn more, visit https://cryptoprocessing.com.
For important disclaimers, see here.
Media Contact
Nadiia Yakubets
info@coinspaid.com
March 31, 2025 11:32 AM
EDT
•
NEW YORK, NY
This Tape Measure App for Home Renovations Just Got Smarter: Preview Your Room Layout in 3D with Measure Tools – AR Ruler
Anyone who's gone through a renovation knows how chaotic it can get. From endless trips to hardware stores and showrooms to juggling suppliers, contractors, and delivery timelines—it’s a whirlwind of small but crucial decisions. Having an interior designer doesn’t mean you’re off the hook, either. Everyone will be waiting for your decisions and preferences, and one thing is certain: you'll need to measure things—a lot.
Whether you're checking dimensions in a new home, sizing up furniture in a showroom, or imagining how a layout you saw online could fit into your own space, having an accurate measuring tool always at hand is a game-changer.
The Solution: A Tape Measure App That Lives in Your Pocket
The Solution: A Tape Measure App That Lives in Your Pocket
With Measure Tools – AR Ruler, you never have to remember to bring a tape measure again. Your phone becomes a smart, augmented reality (AR) ruler you can pull out anytime, anywhere.
Unlike traditional tape measures, which can be awkward (especially on dusty construction sites or in tight spaces), this app lets you measure quickly and comfortably just by pointing your phone’s camera. You don’t need to climb ladders or furniture, crawl into tight spaces, or move heavy items that stand in the way of your measurements.
Measure Tools – AR Ruler is not your average measurement app—it’s a pioneer in the digital measurement space. The camera-based measuring app was launched in 2018 after many years of computer vision experience by the development team at Craftars. Since then, over 900,000 people around the world have used it to measure rooms, preview furniture layouts, calculate distances, and make smarter decisions in construction, real estate, renovation, and interior design.
Whether you're a contractor on a job site, a homeowner redesigning your living room, or an agent showing a property, this AR-powered tool turns your smartphone into a complete space planning assistant.
Key Features
Key Features
- Instant measurements using your phone camera: Quickly measure distances, heights, or object sizes by simply pointing your camera—perfect for on-the-go measurements without needing a physical tape.
- 3D shapes to preview furniture or objects at true scale: Place realistic, full-scale objects as cubes in your space to see how furniture or appliances will actually fit and feel—before you buy.
- Smart modes: lock measurements horizontally or perpendicular to surfaces: Easily measure along the floor or walls with smart axis-locking—great for getting straight lines in cluttered or complex spaces.
- Chained measurements to calculate perimeters and areas: Connect multiple points in sequence to measure entire rooms, plan layouts, or calculate floor space and material needs. Works for complex shapes too, not just simple rectangular rooms.
- Scan floor layout even when obstacles are in the way: Measure the usable floor area accurately, even if furniture or other objects are blocking the view—no need to move anything around.
- Angles: Instantly measure the angle between two segments—useful for checking corners, slopes, or ensuring elements align correctly in your space.
Introducing: Real-Scale 3D Layout Previews
The newest feature in Measure Tools lets you go beyond measuring—now you can preview your entire room layout in 3D.
Instead of guessing whether that beautiful sofa will fit, you can place a virtual object with the exact size of your future purchase directly into your space. This allows you to visualize spacing, flow, and fit before you commit.
While some people try to simulate layouts by placing masking tape or painter’s tape on the floor, this method is time-consuming, messy, and imprecise. You have to measure each side manually, bend down repeatedly to apply tape, and if you want to shift the layout even slightly, you need to remove and redo everything. It leaves sticky residue on the floors and gives you only a flat, 2D outline.
With Measure Tools, you can stand comfortably, place and adjust virtual furniture in seconds, and get a true 3D sense of how the object fits in your space. A few taps replace an hour of crouching and guesswork.
Planning with Pinterest boards or product listings is helpful, but seeing your own space filled in AR is a completely different experience. You’ll immediately spot if something feels too big, too small, or simply wrong for the room. This means fewer mistakes, fewer returns, and less stress.
And if you're ordering custom furniture? Even more reason to be precise. A wrong fit could mean hundreds of dollars lost or weeks of delay for costly adjustments.
Who Can Benefit from the Measure Tools – AR Ruler App
- Contractors & Renovation Pros: Speed up site visits, estimate jobs accurately, and avoid rework.
- Homeowners & DIYers: Plan your dream space with confidence and avoid expensive mistakes.
- Interior Designers: Show clients real-time layout previews and streamline the design process.
- Real Estate Agents: Instantly answer buyers’ questions about fit and layout on the spot.
With Measure Tools, you’ll always be ready—equipped with a powerful digital tool that positions you as a true professional, helps you communicate better, and get the job done faster.
Available Now – Try It on Your Next Project
Available Now – Try It on Your Next Project
Measure Tools – AR Ruler is available on both mobile platforms: the Android measurement app and the iOS tape measure app both include all the powerful features listed above. Whether you’re measuring a wall, planning a kitchen, or decorating a new apartment, this app helps you work smarter, faster, and more confidently.
Since launch, we’ve been continuously updating, refining, and expanding the app—adding new tools to make measuring easier and more intuitive. Much of this progress is thanks to our growing community. We listen closely to user feedback and actively collaborate with professionals in construction, interior design, and real estate to ensure the app evolves to meet real needs on the ground.
Download today and transform your phone into the smartest measuring tool you own. For support, feedback, or custom feature requests, visit the Measure Tools website.
About Measure Tools
Measure Tools is an advanced measuring tape app that turns your smartphone into a versatile tool for measuring distances, calculating areas, and visualizing spaces. With augmented reality (AR), it functions as a virtual ruler, enabling users to take fast and comfortable room measurements using their phone's camera. Whether you're in real estate, construction, interior design, or simply planning your next home project, Measure Tools makes it easy to measure and map out spaces. With features like chained measurements, angle detection, and 3D object placement, it’s the perfect companion for professionals and DIY enthusiasts alike. For more information, visit https://www.measuretools.net.
About Measure Tools
Measure Tools is an advanced measuring tape app that turns your smartphone into a versatile tool for measuring distances, calculating areas, and visualizing spaces. With augmented reality (AR), it functions as a virtual ruler, enabling users to take fast and comfortable room measurements using their phone's camera. Whether you're in real estate, construction, interior design, or simply planning your next home project, Measure Tools makes it easy to measure and map out spaces. With features like chained measurements, angle detection, and 3D object placement, it’s the perfect companion for professionals and DIY enthusiasts alike. For more information, visit https://www.measuretools.net.
Media Contact
George Mincila
hello@measuretools.net
March 31, 2025 9:15 AM
EDT
•
NEW YORK, NY
NextNRG Announces Estimated 139% Year-over-Year Revenue Growth for February 2025
Following the release of its fourth quarter and full-year 2024 financial results, NextNRG, Inc. (NASDAQ: NXXT)—a pioneer in AI-driven energy innovation, transforming how energy is produced, managed, and delivered through its advanced Utility Operating System, smart microgrid technology, wireless EV charging, and on-demand mobile fuel delivery solutions—has reported another month of record performance. The company continues to demonstrate momentum across its smart fueling operations and broader platform of next-generation energy solutions.
In February 2025, NextNRG reported unaudited revenue of approximately $5.09 million, a 139 percent increase over February 2024 and a sequential increase from January, despite fewer operating days. Fuel volumes rose to approximately 1.44 million gallons, up 166 percent year-over-year. The performance marks the second consecutive month of record revenue for the company’s EzFill mobile fueling division.
Recently, NextNRG also reported a 20 percent increase in full-year 2024 revenue to $27.8 million, up from $23.2 million in 2023. Gross profit for the year grew 64 percent to $2.3 million. Fourth quarter revenue rose 21 percent year-over-year to $6.9 million, while gross profit nearly doubled to $652,000. Growth was driven by increased fuel volume, higher-margin delivery operations, and improved pricing discipline.
“We believe our back-to-back record months underscore the power of our growing platform and the momentum we’ve built through strategic expansion. The successful integration of the Shell Oil fleet and our long-term agreement with a global e-commerce leader are now fueling real, measurable growth. As we scale with continued discipline, demand from fleet partners continues to rise, validating our model and vision for the future. With EzFill’s on-demand fueling operating efficiently and NextNRG’s smart energy infrastructure, we are positioned to lead the transformation of how energy is delivered in a connected, AI-driven world,” said Michael D. Farkas, founder and CEO of NextNRG.
As the Company looks ahead to the remainder of 2025, it plans to accelerate its expansion across key verticals including mobile fueling, AI-optimized microgrids, and wireless EV charging. New SaaS contracts and infrastructure deployment initiatives are expected to support recurring revenue growth and long-term scalability.
To find out more about NextNRG, read the latest Q&A here.
A conference call to discuss NextNRG’s full-year 2024 results is scheduled for Monday, March 31, 2025, at 4:30 PM ET.
About NextNRG
NextNRG, Inc. (NASDAQ: NXXT) is Powering What’s Next by implementing artificial intelligence (AI) and machine learning (ML) into renewable energy, next-generation energy infrastructure, battery storage, wireless electric vehicle (EV) charging, and on-demand mobile fuel delivery to create an integrated ecosystem.
At the core of NextNRG’s strategy is its Utility Operating System which leverages AI and ML to help make existing utilities’ energy management as efficient as possible; and the deployment of NextNRG Smart Microgrids, which utilize AI-driven energy management alongside solar power and battery storage to enhance energy efficiency, reduce costs, and improve grid resiliency. These microgrids are designed to serve commercial properties, schools, hospitals, nursing homes, parking garages, rural and tribal lands, recreational facilities, and government properties, expanding energy accessibility while supporting decarbonization initiatives.
NextNRG continues to expand its growing fleet of fuel delivery trucks and national footprint, including the acquisition of Yoshi Mobility’s fuel division and Shell Oil’s trucks, further solidifying its position as a leader in the on-demand fueling industry. NextNRG is also integrating sustainable energy solutions into its mobile fueling operations. The company hopes to be an integral part of assisting its fleet customers in their transition to EV supporting more efficient fuel delivery while advancing clean energy adoption. The transition process is expected to include the deployment of NextNRG’s innovative wireless EV charging solutions.
To find out more visit: www.nextnrg.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement describing NextNRG’s goals, expectations, financial or other projections, intentions, or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "expect," "intends," "will," and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including, but not limited to, those related to NextNRG’s business and macroeconomic and geopolitical events. These and other risks are described in NextNRG’s filings with the Securities and Exchange Commission from time to time. NextNRG’s forward-looking statements involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although NextNRG’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by NextNRG. Except as required by law, NextNRG undertakes no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements.
Disclaimer
Disclaimer
This communication was produced by PRISM MarketView, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its clients’ securities. See www.pcgadvisory.com/disclosures.
Media Contact
PRISM MarketView
info@prismmarketview.com
March 28, 2025 11:10 AM
EDT
•
TALLINN, Estonia
FineVPN Launches New VPN Service Using xRay Protocol for Enhanced Privacy and Security
FineVPN, a leading VPN service provider, is excited to announce the launch of its new VPN service based on the powerful xRay protocol. This innovative addition is designed to enhance user privacy, anonymity, and resistance to blocking, making it an ideal solution for secure internet browsing, streaming, and more.
The xRay protocol, known for its robust traffic encryption and anonymity features, is now available in both Free and Premium packages from FineVPN. The Free plan provides stable and fast connections for basic browsing and streaming without lags, while the Premium plan offers additional features and optimized networks for a superior experience.
Features of FineVPN XRAY
Features of FineVPN XRAY
Free Plan:
- Resistant to blocking
- Traffic encryption
- Anonymity
- Basic servers stable and fast
- Suitable for surfing and streaming without lags
- Available countries: France, India, Pakistan, Seychelles
Premium Plan:
- All features of the Free Plan
- More servers and countries
- Optimized networks for improved performance
- Ad Filter to block unwanted ads
- Accessible with All Time Premium
- Available countries: United States, United Kingdom, France, Netherlands, Germany, Ukraine, Russia, United Arab Emirates, Seychelles, Pakistan, India
FineVPN’s xRay-based VPN is designed to meet the growing demand for secure and private internet access, especially in regions where internet restrictions are common. The company aims to provide users with an enhanced internet experience, prioritizing privacy, reliability, and accessibility.
About FineVPN
About FineVPN
FineVPN is a reliable VPN service provider offering secure internet connections through a wide range of servers worldwide. With its easy-to-use setup and strong encryption protocols, we deliver a seamless browsing experience for both casual and professional users. For more information, visit https://finevpn.org.
Media Contact
Support Team
support@finevpn.org
March 27, 2025 1:54 PM
EDT
•
CHICAGO, IL
First Class Action Lawsuit Filed Against University of Michigan for Massive Privacy Breach Affecting Thousands of Female Athletes
Stinar Gould Grieco & Hensley, PLLC has filed the first class action lawsuit against the University of Michigan, the Regents of the University of Michigan, Matthew Weiss, and Keffer Development Services, LLC, alleging a massive breach of privacy affecting over 3,300 individuals, primarily female student-athletes.
The lawsuit, filed in the United States District Court for the Eastern District of Michigan (Case No. 2:25-cv-10806), alleges that defendants allowed unauthorized access to sensitive personal information, private photographs, and videos of thousands of student-athletes.
According to the complaint, Matthew Weiss, a former University of Michigan employee, allegedly accessed—without authorization—the social media accounts, emails, cloud storage, and personal information of thousands of female student-athletes over approximately eight years (2015-2023). The complaint alleges that Weiss targeted female athletes and downloaded private photographs and videos that were never intended to be shared beyond the plaintiffs' intimate partners.
"This case represents one of the most significant breaches of student-athlete privacy in recent memory," said Parker Stinar, lead attorney for the plaintiffs.
"Our clients placed their trust in the University of Michigan and its vendors, only to have their most personal and private information compromised due to what we allege was negligence and recklessness."
The lawsuit alleges that the University of Michigan, its Regents, and Keffer Development Services failed to implement adequate security measures, proper supervision, or employee monitoring that would have protected the plaintiffs' privacy.
According to the complaint, Weiss allegedly:
- Gained unauthorized access to student-athlete databases maintained by Keffer Development Services
- Downloaded personally identifiable information (PII) and medical data of more than 150,000 athletes
- Obtained passwords used by athletes to access computer systems
- Used this access to download private photographs and videos
The lawsuit includes claims for violations of the Computer Fraud and Abuse Act, the Stored Communications Act, Title IX, and various state laws involving invasion of privacy, negligence, and conversion.
The plaintiffs are seeking damages exceeding $100 million, along with costs, interest, and attorney fees. The class action complaint seeks to represent all persons whose personal information, images, data, social media, or videos were accessed by Weiss without authorization.
"This lawsuit is not only about seeking justice for those whose information was stolen but also about forcing the University of Michigan to confront its systemic failures and ensure such breaches never happen again. The case will hold the institution accountable for its lack of appropriate safeguards and transparency regarding the security of its student-athletes’ personal and medical data.
In the face of such violations, SGGH is committed to turning over every stone in our pursuit of justice. Through litigation, we will uncover the flaws in Michigan’s cyber security protocols that led to this massive breach, and demand real change to protect vulnerable individuals from similar harms in the future.
We will fight relentlessly to secure justice for all those affected." said Parker Stinar, lead attorney for the plaintiffs.
In the face of such violations, SGGH is committed to turning over every stone in our pursuit of justice. Through litigation, we will uncover the flaws in Michigan’s cyber security protocols that led to this massive breach, and demand real change to protect vulnerable individuals from similar harms in the future.
We will fight relentlessly to secure justice for all those affected." said Parker Stinar, lead attorney for the plaintiffs.
This case highlights the growing concern around data privacy and the security of personal information in the digital age, particularly in university settings where students entrust institutions with their personal data.
About Stinar Gould Grieco & Hensley, PLLC
About Stinar Gould Grieco & Hensley, PLLC
Stinar Gould Grieco & Hensley, PLLC is a law firm dedicated to protecting the rights of individuals in complex litigation matters. The firm has extensive experience in class action lawsuits, privacy law, and representing victims of institutional failures. Managing Partner, Parker Stinar, previously led the University of Michigan/Robert Anderson sexual abuse matter which resolved for $490 million dollars for more than 1,000 individuals. For more information, visit https://www.sgghlaw.com.
Media Contact
Lynn Smith
lynn@lynnsmithtv.com
March 27, 2025 12:17 PM
EDT
•
LONDON, United Kingdom
ValueTheMarkets Insights: While Big Pharma Stalls, One Small-Cap Breaks Out
ValueTheMarkets, a trusted resource for retail investors offering financial news, in-depth analysis, and investment insights, today shared insights into small-cap biotech stocks.
In a year where the S&P 500 has slipped -1.78% and biotech giants like Novo Nordisk (NYSE: NVO) are under pressure, Medicus Pharma (NASDAQ: MDCX) is breaking away from the pack. The stock has surged 32% year-to-date, outperforming Eli Lilly’s (NYSE: LLY) respectable 9.55% gain and leaving Novo’s -15.9% slide far behind. But it’s not chasing blockbuster weight loss drugs—it’s targeting a radically different frontier: non-invasive skin cancer treatment.
In a year where the S&P 500 has slipped -1.78% and biotech giants like Novo Nordisk (NYSE: NVO) are under pressure, Medicus Pharma (NASDAQ: MDCX) is breaking away from the pack. The stock has surged 32% year-to-date, outperforming Eli Lilly’s (NYSE: LLY) respectable 9.55% gain and leaving Novo’s -15.9% slide far behind. But it’s not chasing blockbuster weight loss drugs—it’s targeting a radically different frontier: non-invasive skin cancer treatment.
The market's attention remains fixated on obesity drugs, but that trade is looking tired. Novo’s drop reflects valuation fatigue. Lilly’s gains are narrowing. Small-cap biotech moves fast when the story clicks.
Medicus Pharma Ltd (NASDAQ: MDCX) is developing the SkinJect D-MNA patch for basal cell carcinoma (BCC) (1), a proprietary microneedle array that is a non-invasive, painless, and cost-effective alternative to Mohs surgery, the current standard of care. A small, thumb-sized microneedle patch is applied to the skin over the BCC lesion. The patch is painless and easy to administer in a doctor’s office and can be applied during just three weekly 30-minute visits over 2 weeks. This has the potential to provide a simple and affordable solution to BCC patients seeking better treatment options. With over 5 million BCC cases diagnosed annually in the U.S., Medicus Pharma targets a $2 billion share of the $15 billion North American skin cancer market. Its SkinJect patch has projected development costs of $75–$100 million, far below the $648 million industry average (2). Priced at around $1,000, it offers a cost-effective alternative to Mohs surgery ($1,800–$2,500) (3).
Novo Nordisk (NYSE: NVO) just struck a big deal with a Chinese drugmaker, The United Laboratories International Holdings Limited, to license a new weight-loss and diabetes drug, UBT251 (4). The deal could be worth up to $2 billion, with $200 million paid upfront and the rest tied to performance milestones. Novo will also pay royalties if the drug sells well outside of China. United Laboratories retains rights in China, Hong Kong, Macau, and Taiwan, while Novo Nordisk holds exclusive rights elsewhere. Novo Nordisk's new weight-loss drug CagriSema showed 15.7% weight loss in patients with Type 2 diabetes in its most recent trial (5). While effective, the results came in below some analyst expectations, contributing to a negative market reaction.
Eli Lilly (NYSE: LLY) is set to release key results this year from late-stage trials of its experimental weight-loss pill, orforglipron (6). These results are highly anticipated, as the once-daily pill could offer a needle-free option for treating obesity and diabetes. If successful, it may expand access for patients globally and ease supply issues affecting injectable treatments. The pill could also strengthen Eli Lilly’s lead in the fast-growing weight-loss drug market as competitors rush to catch up. Meanwhile, Lilly has recently expanded its cancer drug pipeline by acquiring an experimental PI3K inhibitor from Scorpion Therapeutics (7). This drug, STX-678, targets PI3Ka mutations common in breast, gynecological, and head and neck cancers.
Both Novo and Lilly are now advancing next-generation GLP-1-based therapies, including Novo’s newly licensed UBT251 and Lilly’s injectable retatrutide. Early data from UBT251 show promising double-digit weight loss over a short treatment window, though Lilly’s drug has demonstrated even greater efficacy over longer trials. While Lilly continues to deepen its presence in both obesity and oncology, Novo remains more narrowly focused, with only a limited footprint beyond its core metabolic disease portfolio. The weight-loss space is increasingly defined by heavyweight competition—and fewer fresh angles.
In markets weighed down by macro fatigue and sector rotation, attention gravitates toward headline-grabbing giants, and small caps often get overlooked—until they don’t. While the biggest names fight to meet sky-high expectations, smaller players can deliver outsized returns simply by executing well on underappreciated ideas. These companies don’t need to dominate a $100 billion category to reward investors—they just need to solve a real problem, move quickly, and fly under the radar long enough for the story to catch up to the fundamentals. That’s how some of this year’s most surprising outperformers have pulled well ahead of the S&P 500, which remains down nearly 2% year-to-date. While broader markets churn, select small-cap biotech names are showing that meaningful innovation still gets rewarded. As the weight-loss drug trade gets crowded and priced in, this could be the moment to look beyond the usual suspects.
Discover more about Medicus Pharma and its plans to commercialize its non-invasive SkinJect patch for BCC.
About Digitonic
Digitonic Ltd. is a specialist investor marketing agency dedicated to helping companies reach, engage, and retain investors. From equity crowdfunding to public company investor relations, we support clients at every stage of their capital-raising journey. Our innovative platforms, products, and tools leverage cutting-edge technology to deliver smart, effective investor marketing that drives results. To learn more, visit https://www.digitonic.com.
About ValueTheMarkets
ValueTheMarkets is a trusted resource for retail investors, offering financial news, in-depth analysis, and investment insights. Whether you're exploring stock market trends, researching companies, or seeking strategic insights, our content is designed to keep you informed and engaged. For more information, visit https://www.valuethemarkets.com.
Digitonic Ltd. is a specialist investor marketing agency dedicated to helping companies reach, engage, and retain investors. From equity crowdfunding to public company investor relations, we support clients at every stage of their capital-raising journey. Our innovative platforms, products, and tools leverage cutting-edge technology to deliver smart, effective investor marketing that drives results. To learn more, visit https://www.digitonic.com.
About ValueTheMarkets
ValueTheMarkets is a trusted resource for retail investors, offering financial news, in-depth analysis, and investment insights. Whether you're exploring stock market trends, researching companies, or seeking strategic insights, our content is designed to keep you informed and engaged. For more information, visit https://www.valuethemarkets.com.
Sources:
- Medicus Pharma Investor Presentation, Q1 2025. Accessed February 2025. https://medicuspharma.com/investor-relations/presentations/
- National Library of Medicine. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. https://pmc.ncbi.nlm.nih.gov/articles/PMC5710275/
- Analyst Coverage from Maxim Group, 17 Dec 2024, and Brookline Capital Markets, 23 Dec 2024. Both reports were supplied by Medicus Pharma in February 2025.
(Note: Analyst targets are based on projections and assumptions that may not materialize.) - GlobeNewswire. The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist. March 24, 2025. https://www.globenewswire.com/news-release/2025/03/24/3047656/0/en/The-United-Laboratories-and-Novo-Nordisk-announce-exclusive-license-agreement-for-UBT251-a-GLP-1-GIP-glucagon-triple-receptor-agonist.html
- GlobeNewswire. Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial. March 10, 2025. https://www.globenewswire.com/news-release/2025/03/10/3039539/0/en/Novo-Nordisk-A-S-CagriSema-demonstrates-superior-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-the-REDEFINE-2-trial.html
- CNBC. Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer. March 24, 2025. https://www.cnbc.com/2025/03/24/eli-lilly-to-release-weight-loss-pill-orforglipron-trial-data-.html
- Lilly. Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program. January 13, 2025. https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-scorpion-therapeutics-mutant-selective-pi3ka
IMPORTANT NOTICE AND DISCLAIMER
PAID ADVERTISEMENT
This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Medicus Pharma to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and seventy five thousand US dollars starting 3rd March 2025 for a period of 4 weeks until 28th March 2025 to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.
CHANGES IN SHARE TRADING AND PRICE
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.
NO OFFER TO SELL OR BUY SECURITIES
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.
INFORMATION
Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.
This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.
NO FINANCIAL ADVICE
The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR+ and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.
FORWARD LOOKING STATEMENTS
This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
TERMS OF USE AND DISCLAIMER
By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.
INTELLECTUAL PROPERTY
All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.
AUTHORS: VALUETHEMARKETS
valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.
ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.
Media Contact
Grant Fraser
editor@valuethemarkets.com
March 27, 2025 12:17 PM
EDT
•
LONDON, United Kingdom
ValueTheMarkets Insights: While Big Pharma Stalls, One Small-Cap Breaks Out
ValueTheMarkets, a trusted resource for retail investors offering financial news, in-depth analysis, and investment insights, today shared insights into small-cap biotech stocks.
In a year where the S&P 500 has slipped -1.78% and biotech giants like Novo Nordisk (NYSE: NVO) are under pressure, Medicus Pharma (NASDAQ: MDCX) is breaking away from the pack. The stock has surged 32% year-to-date, outperforming Eli Lilly’s (NYSE: LLY) respectable 9.55% gain and leaving Novo’s -15.9% slide far behind. But it’s not chasing blockbuster weight loss drugs—it’s targeting a radically different frontier: non-invasive skin cancer treatment.
In a year where the S&P 500 has slipped -1.78% and biotech giants like Novo Nordisk (NYSE: NVO) are under pressure, Medicus Pharma (NASDAQ: MDCX) is breaking away from the pack. The stock has surged 32% year-to-date, outperforming Eli Lilly’s (NYSE: LLY) respectable 9.55% gain and leaving Novo’s -15.9% slide far behind. But it’s not chasing blockbuster weight loss drugs—it’s targeting a radically different frontier: non-invasive skin cancer treatment.
The market's attention remains fixated on obesity drugs, but that trade is looking tired. Novo’s drop reflects valuation fatigue. Lilly’s gains are narrowing. Small-cap biotech moves fast when the story clicks.
Medicus Pharma Ltd (NASDAQ: MDCX) is developing the SkinJect D-MNA patch for basal cell carcinoma (BCC) (1), a proprietary microneedle array that is a non-invasive, painless, and cost-effective alternative to Mohs surgery, the current standard of care. A small, thumb-sized microneedle patch is applied to the skin over the BCC lesion. The patch is painless and easy to administer in a doctor’s office and can be applied during just three weekly 30-minute visits over 2 weeks. This has the potential to provide a simple and affordable solution to BCC patients seeking better treatment options. With over 5 million BCC cases diagnosed annually in the U.S., Medicus Pharma targets a $2 billion share of the $15 billion North American skin cancer market. Its SkinJect patch has projected development costs of $75–$100 million, far below the $648 million industry average (2). Priced at around $1,000, it offers a cost-effective alternative to Mohs surgery ($1,800–$2,500) (3).
Novo Nordisk (NYSE: NVO) just struck a big deal with a Chinese drugmaker, The United Laboratories International Holdings Limited, to license a new weight-loss and diabetes drug, UBT251 (4). The deal could be worth up to $2 billion, with $200 million paid upfront and the rest tied to performance milestones. Novo will also pay royalties if the drug sells well outside of China. United Laboratories retains rights in China, Hong Kong, Macau, and Taiwan, while Novo Nordisk holds exclusive rights elsewhere. Novo Nordisk's new weight-loss drug CagriSema showed 15.7% weight loss in patients with Type 2 diabetes in its most recent trial (5). While effective, the results came in below some analyst expectations, contributing to a negative market reaction.
Eli Lilly (NYSE: LLY) is set to release key results this year from late-stage trials of its experimental weight-loss pill, orforglipron (6). These results are highly anticipated, as the once-daily pill could offer a needle-free option for treating obesity and diabetes. If successful, it may expand access for patients globally and ease supply issues affecting injectable treatments. The pill could also strengthen Eli Lilly’s lead in the fast-growing weight-loss drug market as competitors rush to catch up. Meanwhile, Lilly has recently expanded its cancer drug pipeline by acquiring an experimental PI3K inhibitor from Scorpion Therapeutics (7). This drug, STX-678, targets PI3Ka mutations common in breast, gynecological, and head and neck cancers.
Both Novo and Lilly are now advancing next-generation GLP-1-based therapies, including Novo’s newly licensed UBT251 and Lilly’s injectable retatrutide. Early data from UBT251 show promising double-digit weight loss over a short treatment window, though Lilly’s drug has demonstrated even greater efficacy over longer trials. While Lilly continues to deepen its presence in both obesity and oncology, Novo remains more narrowly focused, with only a limited footprint beyond its core metabolic disease portfolio. The weight-loss space is increasingly defined by heavyweight competition—and fewer fresh angles.
In markets weighed down by macro fatigue and sector rotation, attention gravitates toward headline-grabbing giants, and small caps often get overlooked—until they don’t. While the biggest names fight to meet sky-high expectations, smaller players can deliver outsized returns simply by executing well on underappreciated ideas. These companies don’t need to dominate a $100 billion category to reward investors—they just need to solve a real problem, move quickly, and fly under the radar long enough for the story to catch up to the fundamentals. That’s how some of this year’s most surprising outperformers have pulled well ahead of the S&P 500, which remains down nearly 2% year-to-date. While broader markets churn, select small-cap biotech names are showing that meaningful innovation still gets rewarded. As the weight-loss drug trade gets crowded and priced in, this could be the moment to look beyond the usual suspects.
Discover more about Medicus Pharma and its plans to commercialize its non-invasive SkinJect patch for BCC.
About Digitonic
Digitonic Ltd. is a specialist investor marketing agency dedicated to helping companies reach, engage, and retain investors. From equity crowdfunding to public company investor relations, we support clients at every stage of their capital-raising journey. Our innovative platforms, products, and tools leverage cutting-edge technology to deliver smart, effective investor marketing that drives results. To learn more, visit https://www.digitonic.com.
About ValueTheMarkets
ValueTheMarkets is a trusted resource for retail investors, offering financial news, in-depth analysis, and investment insights. Whether you're exploring stock market trends, researching companies, or seeking strategic insights, our content is designed to keep you informed and engaged. For more information, visit https://www.valuethemarkets.com.
Digitonic Ltd. is a specialist investor marketing agency dedicated to helping companies reach, engage, and retain investors. From equity crowdfunding to public company investor relations, we support clients at every stage of their capital-raising journey. Our innovative platforms, products, and tools leverage cutting-edge technology to deliver smart, effective investor marketing that drives results. To learn more, visit https://www.digitonic.com.
About ValueTheMarkets
ValueTheMarkets is a trusted resource for retail investors, offering financial news, in-depth analysis, and investment insights. Whether you're exploring stock market trends, researching companies, or seeking strategic insights, our content is designed to keep you informed and engaged. For more information, visit https://www.valuethemarkets.com.
Sources:
- Medicus Pharma Investor Presentation, Q1 2025. Accessed February 2025. https://medicuspharma.com/investor-relations/presentations/
- National Library of Medicine. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. https://pmc.ncbi.nlm.nih.gov/articles/PMC5710275/
- Analyst Coverage from Maxim Group, 17 Dec 2024, and Brookline Capital Markets, 23 Dec 2024. Both reports were supplied by Medicus Pharma in February 2025.
(Note: Analyst targets are based on projections and assumptions that may not materialize.) - GlobeNewswire. The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist. March 24, 2025. https://www.globenewswire.com/news-release/2025/03/24/3047656/0/en/The-United-Laboratories-and-Novo-Nordisk-announce-exclusive-license-agreement-for-UBT251-a-GLP-1-GIP-glucagon-triple-receptor-agonist.html
- GlobeNewswire. Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial. March 10, 2025. https://www.globenewswire.com/news-release/2025/03/10/3039539/0/en/Novo-Nordisk-A-S-CagriSema-demonstrates-superior-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-the-REDEFINE-2-trial.html
- CNBC. Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer. March 24, 2025. https://www.cnbc.com/2025/03/24/eli-lilly-to-release-weight-loss-pill-orforglipron-trial-data-.html
- Lilly. Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program. January 13, 2025. https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-scorpion-therapeutics-mutant-selective-pi3ka
IMPORTANT NOTICE AND DISCLAIMER
PAID ADVERTISEMENT
This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Medicus Pharma to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and seventy five thousand US dollars starting 3rd March 2025 for a period of 4 weeks until 28th March 2025 to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.
CHANGES IN SHARE TRADING AND PRICE
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.
NO OFFER TO SELL OR BUY SECURITIES
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.
INFORMATION
Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.
This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.
NO FINANCIAL ADVICE
The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR+ and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.
FORWARD LOOKING STATEMENTS
This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
TERMS OF USE AND DISCLAIMER
By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.
INTELLECTUAL PROPERTY
All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.
AUTHORS: VALUETHEMARKETS
valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.
ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.
Turn your news into performance
EZ Newswire is the only news platform connecting the most influential organizations with the most trusted media outlets.
Get started